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ORIGINAL ARTICLEPhysicochemical and Pharmacokinetic Profiles of Gadopiclenol
A New Macrocyclic Gadolinium Chelate With High T1 RelaxivityCaroline Robic, PhD,* Marc Port, PhD,† Olivier Rousseaux, PhD,* Stéphanie Louguet, PhD,*
Nathalie Fretellier, PhD,* Sarah Catoen, PhD,* Cécile Factor, PhD,* Soizic Le Greneur, PhD,*
Christelle Medina, PhD,* Philippe Bourrinet, PharmD,* Isabelle Raynal, PhD,*
Jean-Marc Idée, PharmD, MS,* and Claire Corot, PharmD, PhD*Abstract: Objectives:We aimed to evaluate gadopiclenol, a newly developed ex-
tracellular nonspecific macrocyclic gadolinium-based contrast agent (GBCA) hav-
ing high relaxivity properties, which was designed to increase lesion detection and
characterization by magnetic resonance imaging.
Methods: We described the molecular structure of gadopiclenol and measured
the r1 and r2 relaxivity properties at fields of 0.47 and 1.41 T in water and human
serum. Nuclear magnetic relaxation dispersion profile measurements were
performed from 0.24 mT to 7 T. Protonation and complexation constants
were determined using pH-metric measurements, and we investigated the
acid-assisted dissociation of gadopiclenol, gadodiamide, gadobutrol, and
gadoterate at 37°C and pH 1.2. Applying the relaxometry technique (37°C,
0.47 T), we investigated the risk of dechelation of gadopiclenol, gadoterate,
and gadodiamide in the presence of ZnCl2 (2.5 mM) and a phosphate buffer
(335 mM). Pharmacokinetics studies of radiolabeled 153Gd-gadopiclenol
were performed in Beagle dogs, and protein binding was measured in rats,
dogs, and humans plasma and red blood cells.
Results: Gadopiclenol [gadolinium chelate of 2,2′,2″-(3,6,9-triaza-1(2,6)-
pyridinacyclodecaphane-3,6,9-triyl)tris(5-((2,3-dihydroxypropyl)amino)-5-
oxopentanoic acid); registry number 933983-75-6] is based on a pyclen mac-
rocyclic structure. Gadopiclenol exhibited a very high relaxivity in water
(r1 = 12.2 mM
−1·s−1 at 1.41 T), and the r1 value in human serum at 37°C
did not markedly change with increasing field (r1 = 12.8 mM
−1·s−1 at
1.41 T and 11.6 mM−1·s−1 at 3 T). The relaxivity data in human serum did
not indicate protein binding. The nuclear magnetic relaxation dispersion profile
of gadopiclenol exhibited a high and stable relaxivity in a strong magnetic field.
Gadopiclenol showed high kinetic inertness under acidic conditions, with a
dissociation half-life of 20 ± 3 days compared with 4 ± 0.5 days for
gadoterate, 18 hours for gadobutrol, and less than 5 seconds for gadodiamide
and gadopentetate. The pharmacokinetic profile in dogs was typical of extracel-
lular nonspecific GBCAs, showing distribution in the extracellular compartment
and no metabolism. No protein binding was found in rats, dogs, and humans.
Conclusions: Gadopiclenol is a new extracellular and macrocyclic Gd chelate
that exhibited high relaxivity, no protein binding, and high kinetic inertness.Received for publication January 21, 2019; and accepted for publication, after revision,
February 21, 2019.
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nonspecific GBCAs.
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T hirty years after their introduction, it is indisputable that the use ofnonspecific gadolinium-based contrast agents (GBCA) in neuro-
logical, spinal, abdominal, cardiac, and vascular magnetic resonance
imaging (MRI) has substantial benefits for evidence-based disease
management.1 Notably, MRI with GBCA-based contrast enhancement
is crucial for detecting small brain metastases.2
Metastatic brain lesions are, by far, the most common type of
central nervous system (CNS) tumors in adults. Population-based stud-
ies indicate incidence rates ranging from 8.3 to 14.3 per 100,000 popu-
lation, and brain metastases affect 8.5% to 9.6% of cancer patients.
Moreover, these values are probably underestimated.3 New imaging
modalities are associated with a rising incidence of known CNS metas-
tases.3 Neuroimaging is highly dependent on GBCA administration,
which dramatically improves CNS lesion detection and depiction, and
thus facilitates diagnosis, sometimes enables determination of tumor
grade and may guide the treatment.4
It was previously a common strategy to increase the GBCA dose
to improve sensitivity during neuroimaging procedures.4 Improved im-
ages can also be obtained by using both a higher GBCA dose and a
higher magnetic field (3 T vs 1.5 T).5 Gadolinium-based contrast agents
were long considered one of the safest classes of drugs.6 However, this
perception changed in 2006 after reports that prior GBCA adminis-
tration is causally linked to the seriously debilitating disease
nephrogenic systemic fibrosis (NSF).7–9 Further investigations re-
vealed that NSF was specifically associated with the use of linear
GBCAs.10,11 Gadolinium-based contrast agents are classified as lin-
ear or macrocyclic agents based on the molecular structure of their
polyazapolycarboxylic ligand.12 Linear GBCAs are characterized
by a lower kinetic stability than macrocyclic GBCAs.12 Most pre-
clinical studies performed in clinically relevant in vivo models sup-
port a causal role of linear but not macrocyclic GBCAs in NSF.13–16
The gradual dissociation of linear GBCAs has been observed in
vivo,15,16 andGd versus endogenous metal transmetallation is proposed
as a likely trigger of the proinflammatory and profibrotic pathways in-
volved in NSF.17 It was recently reported that repeated administrations
of GBCAs (almost exclusively of the linear category) lead to accumula-
tion in specific areas of the brain, mostly in the dentate nucleus and the
globus pallidus, but also at other CNS sites after repeated administra-
tions of linear GBCAs.18,19 Biospeciation studies with linear GBCAs
have concluded that the brain tissue contains multiple species of
Gd—including chelated and soluble, dissociated and insoluble, and dis-
sociated and soluble—which are likely macromolecule-bound.20–22
The European Union has suspended the use of all linear non-
specific GBCAs, except those dedicated to specific indicationswww.investigativeradiology.com 475
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(FDA) has also recognized that linear GBCAs are associated with
greater retention for a longer duration compared with macrocyclic
GBCAs, and has followed a different approach. The FDA states that
healthcare professionals should consider the Gd-retention character-
istics of each agent when choosing a GBCA for at-risk patients. The
FDA has also requested that radiologists minimize repeated GBCA
imaging studies when possible, particularly in closely spaced
MRI investigations.24
Because procedures using high doses of existing GBCAs are less
common, there is a need for new extracellular nonspecific GBCAs
allowing detection of more metastatic lesions using high magnet fields
and without increasing the dose.4 One obvious way of dealing with this
issue is to increase the longitudinal relaxivity of GBCAs to increase the
contrast between the lesion and background healthy parenchyma with
the classic dose of 0.1 mmol Gd/kg.25,26 A sufficient relaxivity increase
could even enable reduction of the Gd dosewithout lowering the current
efficacy associated with extracellular and nonspecific GBCAs.4 All ex-
tracellular GBCAs currently on the market have roughly similar
relaxivity properties,27 and their use at higher doses is limited due to po-
tential safety concerns.
Gadopiclenol, a newmacrocyclic GBCA characterized by a very
high r1 relaxivity, is currently under development. In the present article,
we aimed to summarize the chemical, physicochemical, and nonclinical
pharmacokinetic data regarding gadopiclenol.MATERIALS AND METHODS
Osmolality
The osmolality of a 10-μL sample of gadopiclenol (0.5-M solu-
tion) was determined using a Vapro pressure osmometer (Wescor Inc,
Logan, UT) pressure. Before each use, the osmometer was calibrated
with 3 standards (Opti-Mole; 100, 290, and 1000 mOsm/kg H2O).
Measurement was performed in triplicate.
Viscosity
The viscosity was assessed using a Kinexus rotative rheometer
(Malvern Panalytical SARL, Orsay, France) at 37°C. The gadopiclenol
solution (0.5 M) was loaded between a 60-mm and 2-degree cone and
plate. Stresses between 1 and 5 Pa were applied. For each stress, the
resulting shear rate was measured. The slope of the curve stress as a
function of shear rates gave the viscosity of the test sample.
Log P Value (n-Octanol/Water)
Gadopiclenol was brought into solution in a 50/50 mixture of
n-octanol and pH 7.4 phosphate-buffered saline. Mixture was main-
tained at 37°C during 24 hours under continuous stirring. Subse-
quently, the 2 phases were taken. Gadopiclenol concentration was
then measured in both media by UHPLC (ultra–high-performance liquid
chromatography) technique: UHPLCWaters using a column Cortecs T3
150  2.1 mm, 1.6 μm (Waters SAS, Guyancourt, France).
Relaxivity Measurements at 20 and 60 MHz
The longitudinal relaxivity of the Gd chelate gadopiclenol was
determined based on the spin lattice relaxation time (T1). T1 was
measured using Bruker Minispec mq20 and mq60 analyzers (Bruker
Biospin, Wissembourg, France) operating at frequencies of 20 MHz
(0.47 T) or 60 MHz (1.41 T). In water or human serum, we prepared
gadopiclenol solutions at 6 Gd concentrations: 0.5, 1.0, 2.0, 3.0, 4.0,
and 5.0 mM. T1 measurements were performed for the 6 concen-
trations, using the standard inversion recovery pulse sequence
(180°-τ-90°), with the temperature maintained at 37°C ± 0.1°C.
T1 was calculated from a monoexponential plot of time versus signal
intensity. The longitudinal relaxivity was calculated from the slope of476 www.investigativeradiology.comthe regression line obtained by plotting 1/T1–1/T1dia versus the con-
centration of the complex, using the least-squares fitting method.
We determined the transverse relaxation time (T2) using the stan-
dard Carr-Purcell-Meiboom-Gill pulse sequence (90°-τ-180°).28,29 T2
relaxation time was calculated from the exponential curve of time versus
signal intensity, measured for 6 concentrations. The transverse relaxivity
value was calculated from the slope of the regression line obtained by
plotting 1/T2–1/T2dia versus the concentration of the complex, using
the least-squares fitting method.
Error bars on the relaxivity datawere estimated at ±6% via an in-
ternal study considering 9 independent samples with measurements
performed by 3 experimenters (3 samples each) with Gd dosage via in-
ductively coupled plasma-atomic emission spectroscopy of the highest
concentrated samples (5 mM).Nuclear Magnetic Relaxation Dispersion
Profile Measurements
Proton nuclear magnetic relaxation dispersion (NMRD) profiles
were determined using a Stelar Spinmaster FFC fast-field-cycling
NMR relaxometer (Stelar, Mede [PV], Italy) over a magnetic field
strength range of 0.24 mT to 0.24 T. Measurements were performed
using 0.6-mL samples in Pyrex tubes with a 10-mm optical dimension.
We additionally obtained relaxation rates using Minispec relaxometers
mq20 (20 MHz, 0.47 T) and mq60 (60 MHz, 1.41 T) and a Bruker
AMX-300 spectrometer (300 MHz). Nuclear magnetic relaxation dis-
persion profiles were determined using Mons University equipment.
Values at 3 T were extrapolated from NMRD profiles. Because these
measurements were performed at only one concentration, the error bars
were estimated at ±10% (internal study on 9 samples with 3 experi-
menters). Proton NMRD curves were fitted using data processing
software that included various theoretical models describing nuclear
relaxation phenomena.Thermodynamic Stability
For the determination of protonation and complexation constants,
we performed pH-metric measurements using a thermoregularized cell
(25°C ± 0.1°C). An argon stream was run over the solution to avoid car-
bon dioxide dissolution.We used aMetrohm type T glass microelectrode
(Metrohm, Herisau, Switzerland) with a low alkaline error. The proce-
dures and apparatus used for potentiometric measurements have been
previously described.30 The ionic product of water (pKw = 13.78, at
25°C ± 0.1°C in 0.1MNMe4Cl) was determined from titrations of acetic
acid with a CO2-free NMe4OH solution. The protonation constants of the
gadopiclenol ligand were determined from 8 titrations, with ligand con-
centrations ranging from 1 to 5 mM in the presence of HCl.
We determined the gadopiclenol constant using 5 series of
40 solutions of Gd3+ and ligand (with ligand concentrations of
7.6  10−4 mol/L to 1.15  10−3 mol/L) plus HCl. These solutions
were prepared in stoppered flasks under argon. The total ligand quantity
was always slightly greater than the Gd3+ quantity to prevent precipita-
tion of the hydroxide Gd(OH)3. The pH of the solutions was adjusted to
values ranging from 2 to 8 by addition of a 5  10−2 M NMe4OH so-
lution. After a 30-day stabilization period at 37°C, the solutions were
maintained at 20°C for 1 day before pH measurement.
Protometric data were processed by using the PROTAF pro-
gram31 to obtain the best-fit chemical model and refined overall sta-
bility constants. The PROTAF program is based on the weighted
least-squares of the residues of the experimental variables (volume
of titrant, pH), and allows simultaneous processing of 10 titrations,
each including 150 pairs of data (volume, pH).
All experiments were performed at Reims, France in the Institute
of Molecular Chemistry.© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
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We investigated the acid-assisted dissociation of the Gd che-
lates (concentration of 8  10−6 M) in a hydrochloric acid solution
(37°C, pH 1.2) under pseudo–first-order conditions without control
of the ionic strength, by following Gd release in the solution.
From an initial 150-mL solution, a 25-mL aliquot was withdrawn
and mixed with 1 mL of Arsenazo III [2,2′-(1,8-dihydroxy-3,6-
disulfonaphthylene-2,7-bisazo)bisbenzenearsonic acid,2,7-bis(2-
arsonophenylazo) chromotropic acid solution; concentration of
5.3  10−4 M] without any buffer addition. Fifteen minutes after
mixing, spectrometric measurement was assayed at 654 nm in a
10-mm cell. This measurement was performed for each point
(Fig. 3). We compared gadopiclenol with gadoterate meglumine
(macrocyclic GBCA, Dotarem 0.5 M; Guerbet, Villepinte, France),
gadobutrol (macrocyclic GBCA, Gadavist/Gadovist 1 M; Bayer, Berlin,
Germany), and gadodiamide (linear GBCA, Omniscan 0.5 M; GE
Healthcare, Chalfont St Giles, United Kingdom).
Dechelation in the Presence of Phosphate and Zn2+
We added 5 mL of a 2.5-mM Gd chelate solution to 5 mL of a
2.5-mMZnCl2 solution, which were both freshly prepared in phosphate
buffer (pH 7, 335mM).Measurement of the relaxivity at T0 of this mixture
was performed extemporaneously. The mixture was then kept at 37°C. At
various time-points, 330-μL aliquots werewithdrawn and the T1 relaxation
time was measured at 37°C. Relaxivity was measured at 20 MHz (ie.
0.47T) using aBrukerMinispecmq20 instrument. Gadopiclenolwas com-
pared with gadoterate meglumine and gadodiamide.
Pharmacokinetics Studies
Pharmacokinetic evaluation was performed using gadopiclenol
radiolabeled with the gamma emitter 153Gd. 153Gd-gadopiclenol (stated
radiochemical purity >98%, specific activity 10.39 mCi/mmol) was
prepared by Chelatec SAS, Saint Herblain, France, as a solution at a
concentration of 0.428 mmol Gd/mL. All samples were subjected to
gamma counting for 1 mn using an automatic controlled gamma coun-
ter (Packard Cobra II Auto Gamma, PerkinElmer, Waltham, MA) with
correction for background and counter efficiency. We acquired the total
radioactivity and sampleweight data using the DebraManagement Sys-
tem, versions 5.2 and 5.7 (LabLogic Systems Limited, Sheffield,
United Kingdom).
The regulations conformed to the European Convention for the
Protection of Vertebrate Animals Used for Experimental and Other Sci-
entific Purposes (Strasbourg, Council of Europe) and achieved the stan-
dard of care required by the US Department of Health and Human
Services' Guide for the Care and Use of Laboratory Animals.
Plasma Pharmacokinetics
We evaluated plasma pharmacokinetics in 3 male and 3 female
Beagle dogs (age, 5–6 months; body weight, 7.4–10.5 kg; Charles
River, Edinburgh, United Kingdom). Animals received an intravenous
(IV) bolus injection (cephalic vein) of 0.2 mmol Gd/kg of 153Gd-
gadopiclenol. Blood samples were collected into heparinized tubes by
jugular vein venipuncture at 5, 15, and 30 minutes, and 1, 2, 4, 6, 8,
24, and 48 hours postdose.
Excretion
To assess gadopiclenol elimination, the animals were housed sin-
gly in stainless steel metabolism cages, specially designed for the quan-
titative collection of urine and feces. Except for a period of fasting from
overnight predose to 4 hours postadministration, a daily allowance of
400 g of a standard laboratory diet of known formulation (Harlan
Teklad Global Diet, code 2021C) and domestic mains tap water were© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.available ad libitum. Holding and study areas had automatic control
of light cycles and temperature. Light hours were 7:00 AM to 7:00 PM.
Ranges of temperature and humidity measured during the study were
20°C to 22°C and 24% to 50%, respectively. We administered 153Gd-
gadopiclenol intravenously to Beagle dogs (0.2 mmol Gd/kg; 3 males
and 3 females). Urine was collected before IV administration, at 0 to
6 hours and 6 to 24 hours postdose, and then at 24-hour intervals up
to termination at 168 hours. Feceswere quantitatively collected predose,
and then at 24-hour intervals up to termination. Cages were washed
daily with water following each sample collection. Cage debris was col-
lected at 168 hours. All samples were retained for analysis. Total radio-
activity levels weremeasured in all collected samples. Urine and plasma
samples were analyzed for potential metabolites by HPLC. High-
performance liquid chromatography was conducted using an Agilent
1100 Series Liquid chromatograph radiodetector and Packard Model
150TR flow scintillation analyzer (Packard, Downers Grove, IL) at 4°
C with a Symmetry C18 column.
Pharmacokinetic Parameter Calculation
The concentration data from urine and plasma were used to
calculate selected pharmacokinetic parameters with WinNonlin
pharmacokinetic software, version 5.2.1 (Pharsight Corp, Sunnyvale,
CA). We implemented a noncompartmental approach consistent with
the IV bolus route of administration. Parameters were estimated using
actual sampling times relative to the end of each dose administration.
We calculated the area under the curve from the plot of plasma total
radioactivity versus time, using the linear trapezoidal method with
linear interpolation.
Protein Binding
To evaluate the in vitro binding of 153Gd-gadopiclenol to plasma
proteins and blood cells of rats, dogs, and humans, we performed equi-
librium dialysis at nominal concentrations of 0.01, 0.1, 1, and 5 μmol/
mL (incubation in a water bath set to maintain a temperature of 37°C
for 2 hours). After incubation, duplicate aliquots of each half-cell com-
partment were assayed for radioactivity to determine the plasma protein
binding or association with blood cells.RESULTS
Chemical Structure and Synthesis
Gadopiclenol (Guerbet, Villepinte, France, patent number
EP 1931 673 B1, page 8, example 2) is a gadolinium chelate of
2,2′,2″-(3,6,9-triaza-1(2,6)-pyridinacyclodecaphane-3,6,9-triyl)
tris(5-((2,3-dihydroxypropyl)amino)-5-oxopentanoic acid) (regis-
try number 933983-75-6; Fig. 1). It has a pyclen-based macrocy-
clic structure that is highly stable in terms of Gd dissociation and
exhibits high relaxivity due to improved water access to the Gd
ion. Its molecular weight is 970.11 g/mol, when calculated without
the 2 water molecules that coordinate in solution.
Pyclen (3,6,9-triaza-1(2,6)-pyridinacyclodecaphane) (regis-
try number 78668-34-5) was alkylated with 3 equivalent of diethyl
2-bromopentanedioate, and the obtained hexaester was saponified to
generate the corresponding hexacarboxylic acid derivative. The
polyacid was complexed with 1 equivalent of Gd (Gd2O3), and this
complex was used in a peptidic coupling reaction with 3 equivalents of
3-aminopropane-1,2-diol to yield the desired hydrophilic and stable
macrocyclic chelate.
The molecular structure (Fig. 1) exhibits 6 asymmetric centers
that can display 64 stereoisomers in solution.
Gadopiclenolwas designed to provide optimal properties regard-
ing its application in MRI, especially in terms of efficacy and safety.www.investigativeradiology.com 477
FIGURE 1. Chemical structure of gadopiclenol [gadolinium chelate of 2,2′,2″-(3,6,9-triaza-1(2,6)-pyridinacyclodecaphane-3,6,9-triyl)tris(5-((2,3-
dihydroxypropyl)amino)-5-oxopentanoic acid)]. The PCTA parent structure is shown in red. Two water molecules are included to show the
coordination in solution.
Robic et al Investigative Radiology • Volume 54, Number 8, August 2019Osmolality, Viscosity, and Hydrophilicity (Log
P n-Octanol/PBS)
Gadopiclenol exhibited an osmolality of 843 mOsm/kg H2O.
Its log P value in n-octanol/PBS was of −4.2 and its viscosity was
7.6 mPa·s (Table 1).
Relaxivity in Different Media
Relaxivity values of gadopiclenol in water and in human serum
at 3 different magnetic fields (0.47, 1.5, and 3 T) are displayed in Table 1.
Gadopiclenol exhibited a high r1 relaxivity in water and human se-
rum. The relaxivity data in human serum suggested no protein
binding (Table 1).
Thermodynamic and Conditional Constants
Gadopiclenol conditional constant at pH 7.4 was calculated from
the measured thermodynamic constant and from the 4 protonation con-
stants of the ligand (Table 2).
Nuclear Magnetic Relaxation Dispersion Profile
Gadopiclenol exhibited an NMRD profile with a high relaxivity,
which was stable at high clinical magnetic field (Fig. 2).
Kinetic Stability Under Acidic Conditions
Experiments were performed using gadopiclenol, gadoterate,
gadobutrol, and gadodiamide at a highly acidic pH. Figure 3 shows
the kinetics of dissociation of these Gd chelates. Gadopiclenol exhib-
ited the highest kinetic stability with a dissociation half-life of 20 ± 3
days at pH 1.2 (Table 1).
Kinetic Dissociation in the Presence of Phosphate and
Endogenous Cation (Zn2+)
In the presence of Zn2+ and phosphate, gadodiamide exhibited a
sharp decrease of the r1(t)/r1(t0) ratio. Conversely, the relaxivities of
gadopiclenol and gadoterate remained constant over the experimental
period in the presence of Zn2+ and phosphate (Fig. 4).478 www.investigativeradiology.comPharmacokinetics Studies
Plasma Pharmacokinetics
Table 3 presents the main plasma pharmacokinetics parameters.
Figure 5 shows the mean levels of total radioactivity in plasma after bo-
lus administration of 153Gd-gadopiclenol in dogs. The highest mean
plasma level of total radioactivity (Tmax) was observed at 5 mn postdose
(first sampling). This level then showed a rapid biexponential decline
over the first 24 hours postdose. No sex difference was found. The dis-
tribution volume was consistent with gadopiclenol distribution within
the extracellular water volume.Excretion
The major excretion route of total radioactivity was via urine.
The mean percentages of administered radioactivity excreted by
168 hours postdose were 93.9% in urine and 5.7% in feces. Total excre-
tion was rapid, with approximately 100% of the administered dose ex-
creted during the first 24 hours postdose.
The recovery data from one female dog was excluded from the
mean calculations due to the low recoveries in this animal. This might
be due to loss of urine at collection as the low recovery was particularly
evident in the first urine collection (0–6 hours).Metabolism
High-performance liquid chromatography analysis re-
vealed the presence of only unchanged gadopiclenol in plasma and
urine samples.Protein Binding
Over the investigated concentration range (0.01–5 μmol/mL), we
detected negligible binding of 153Gd-gadopiclenol to plasma proteins in
all species (0% in rats, 1.4% in dogs, and 0.5% in humans), which was
independent of the concentration. Binding of 153Gd-gadopiclenol to red
blood cells was also low in all species (6%–16.7% in rats, 0%–3.2%© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
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TABLE 2. Successive Protonation Constants of Gadopiclenol Ligand
(Noted LH4) at 25°C in NMe4Cl Medium (0.1 mol/L)
Corresponding Chemical Equilibrium Log Kprot
L4− + H3O
+⇄ LH3− + H2O 10.57
LH3− + H3O
+⇄ LH2−2 + H2O 5.99
LH2−2 + H3O
+⇄ LH3
− + H2O 4.06
LH−3 + H3O
+⇄ LH4 + H2O 2.07
Robic et al Investigative Radiology • Volume 54, Number 8, August 2019in dogs, and 0%–0.1% in humans), and was also independent of
the concentration.
DISCUSSION
Gadopiclenol is a new nonspecific macrocyclic GBCA that was
designed to exhibit both high relaxivity and high kinetic inertness. Its
low-molecular-weight structure and lack of interaction with plasma
proteins enable its use for several clinical indications including CNS
and breast cancer.
The finding that linear GBCAs are associated with NSF and Gd
retention at CNS sites has sparked new interest in alternative MRI con-
trast agents. Possible options include iron oxide nanoparticles (NPs),
iron chelates, or manganese (Mn)-based contrast agents.32–34 Acute
and subacute toxicity data are still needed to estimate the safety profile
of iron chelates.33 Iron oxide NPs and Mn-based agents have been the
subject of considerable research, and are not yet in clinical use for
safety, regulatory, economic, or industrial reasons.35
The molecular structure of gadopiclenol was considered to of-
fer the best compromise to get good stabilities (thermodynamic and
kinetic), high r1 relaxivity (around 2 that of currently available
GBCAs), and the classical characteristics of a nonspecific non–
protein-binding agent; that is, low molecular weight and favor-
able physicochemical properties, including high solubility and lowFIGURE 2. Nuclear magnetic relaxation dispersion profiles of gadopiclenol and
±10% for relaxivity measurements.
480 www.investigativeradiology.comosmolality in water. To ensure good kinetic inertness, gadopiclenol
was designed with a macrocyclic ligand structure, which is based on a
parent PCTA ligand [2,2′,2″-(3,6,9-triaza-1(2,6)-pyridinacyclodecaphane-
3,6,9-triyl)triacetic acid] that contains a pyridine moiety in the macro-
cyclic polyamine backbone.36 This PCTA structure theoretically permits
the coordination of 2 water molecules in the so-called inner sphere. In
Figure 1, the PCTA parent structure is shown in red with 7 coordinated
arms to Gd3+ and with the 2 water molecules that can complete the 9
coordination links of Gd3+.
The relaxation rate r1 reflects the efficiency of an MRI contrast
agent, and is determined by 2 factors. One is the contribution of water
molecules directly linked to Gd3+, termed the inner sphere contribution,
as described by the Solomon-Bloembergen-Morgan (SBM) theory. The
other is the contribution of water molecules that diffuse near the Gd3+
atom but without direct linkage, termed the outer sphere contribution,
as described by the Freed theory.37 In the SBM equation, the number
of water molecules coordinated to Gd3+ is directly proportional to the
relaxation rate:
R1 ISð Þ ¼ q CA½ H2O½ 
1
T1m þ τm : Equation 1
where (IS) refers to the inner sphere, q is the hydration number (number
of bound water nuclei per Gd ion), [CA] is the contrast agent concentra-
tion, [H2O] is the water molecule concentration, T1m refers to the T1 re-
laxation time value of the coordinated water protons, and τm is the
residence time of the water molecule in the inner sphere.6
T1m depends on field frequency, as well as on the global corre-
lation time (τc), which is governed by 3 main mechanisms: the rota-
tional diffusion of the complex (1/τr), the thermal transition of the
unpaired electrons of Gd between excited and ground states (1/τs),
and the water exchange (1/τm). The global correlation time τc is calcu-
lated as follows:
1
τc
¼ 1
τr
þ 1
τS
þ 1
τm
: Equation 2gadoterate in solution with water at 37°C. Bars indicate an uncertainty of
© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
FIGURE 3. DissociatedGd3+ (mol%) over time for gadopiclenol, gadoterate, gadobutrol, and gadodiamide under acidic conditions. The concentration of
Gd chelates was 8  10−6 mol/L in HCl (pH 1.2). Measurements were performed at 37°C using Arsenazo III as the colorimetric indicator.
Investigative Radiology • Volume 54, Number 8, August 2019 Gadopiclenol Physicochemical Profilewhere τr represents the rotational correlation time of the Gd chelate, τs
is the electronic relaxation time, and τm is the lifetime of the solvent
molecule in the Gd chelate.
Examining Equations 1 and 2, it is clear that the residence time
should be long enough to increase the probability of relaxation but suf-
ficiently short to allow the relaxed water molecule to undergo efficient
exchangewith the bulk. Equation 2 shows that of the 3 mechanisms, the
fastest process will dominate. With low-molecular-weight complexes,
the r1 relaxivity value is driven by the τr component, since small mol-
ecules exhibit fast rotational diffusion.6 Gadopiclenol was designed with
small hydrophilic pendant arms to increase its global hydrodynamic size.FIGURE 4. Temporal evolution (up to 5 days) of the R1(t)/R1(t0) ratio for gad
relaxation rate. Concentration of GBCAs and ZnCl2 was 2.5 mM in phosphate
with a field of 0.47 T.
© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.This reduces the rotational diffusion (1/τr), allowing 1/τS to be taken into
account in Equation 2, and thus increasing the relaxivity according to the
SBM equations. Moreover, these polyalcohol arms may increase the
number of water molecules linked by the second sphere mechanism, fur-
ther increasing the r1 relaxivity of gadopiclenol.
38
Gadopiclenol had an r1 longitudinal relaxivity of 11.6 mM
−1·s−1
in human serum at 3 Tand 37°C, making it the extracellular GBCAwith
the highest paramagnetic effect. The NMRD profile of gadopiclenol
(Fig. 2) shows its very high r1 relaxivity value up to high magnet fields
(10.68 mM−1·s−1 at 300MHz, ie, 7 T field). This pattern is representative
of Gd chelates with q = 2, which is a different type of molecular structureopiclenol, gadoterate, and gadodiamide, where R1 is the longitudinal
buffer (pH 7.0, 335 mM). Measurements were performed at 37°C and
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TABLE 3. Results of Pharmacokinetics Studies With 153Gd-
Gadopiclenol in Beagle Dogs (Data on 3 Males and 3 Females,
Pooled)
Experimental Conditions in Dogs
Dose, mmol Gd/kg 0.2
Number and sex of animals 6 (3 males + 3 females)
Parameters
t1/2 β, h 0.99 ± 0.01
AUC0-inf, nmol equ·h·mL
−1 957 ± 77
Clt, mL/h/kg 206 ± 16
CLr, mL/h/kg* 179 ± 25
Vdss, mL/kg 239 ± 8
Values are given as mean ± SD.
Slope-dependent parameters: AUC0-inf, t1/2 b, Clt, Vd, Vdss, calculated
using data to 8 hours. Renal clearance was calculated using plasma and urine
values over 6 hours.
*n = 5 dogs, one female dog excluded from calculation of renal clearance due
to unreliable urinary excretion data.
t1/2 b indicates the apparent terminal elimination half-life; AUC, area under the
curve; Clt, total clearance; CLr, renal clearance; Vdss, volume of distribution at
steady-state.
Robic et al Investigative Radiology • Volume 54, Number 8, August 2019compared with other commercial GBCAs that are characterized by a
q = 1 hydration number structure.
The thermodynamic constant log Ktherm (at very basic pH) of
gadopiclenol is of 19.7. Low values of the protonation constants of
the gadopiclenol ligand (Table 2), which are in the same range as
those given for PCTA,39 lead to a conditional constant log Kcond
value at physiological pH 7.4 of 15.5. This value is in the range
of currently marketed GBCAs.12
Under physiological conditions (pH 7.4), GBCAs have low
dissociation rates, such that potentially released free Gd concentra-
tions are not quantifiable within an acceptable experimental time.
Therefore, experiments to assess and compare the kinetic stabilities of
GBCAs are conventionally performed under acidic conditions, in the
presence of HCl (pH 1.2) and at 37°C, where dissociation rates are
faster.12 Gadolinium chelate dissociation, mediated by either spontaneousFIGURE 5. Mean (±SD) levels of total radioactivity in plasma plotted versus tim
(0.2 mmol Gd/kg) to Beagle dogs (3 males and 3 females).
482 www.investigativeradiology.comor proton-assisted mechanisms,12 is a pseudo–first-order reaction. The
dissociation rate is calculated by the following equation:
−
d GdL½ 
dt
¼ kobs  GdL½ : Equation 3
where [GdL] is the Gd chelate concentration, and kobs is the dissociation
constant. Using this equation, the dissociation constant may be graphi-
cally determined by plotting ln([GdL]0 − [Gd3+]) as a function of time.
The half-life time for Gd chelate dissociation (t1/2) can be calculated
as follows:
t1=2 ¼ ln 2ð Þkobs : Equation 4
The model relevance, as well as the dissociation behavior of gadoterate
and gadodiamide, has been discussed elsewhere.12
The dissociation curves obtained at pH 1.2 (Fig. 3) demonstrate
that the dissociation rates of the Gd chelates were highly dependent on
the structural nature of the GBCA ligand. Under our experimental
conditions, gadodiamide dissociation was almost immediate, and
did not enable determination of kobs and t1/2 values. Compared with
the linear GBCA gadodiamide, macrocyclic Gd chelates (gadobutrol
and gadoterate) exhibited considerably longer dissociation half-
lives. Of all tested GBCAs, gadopiclenol had the longest dissocia-
tion half-life, suggesting a very high kinetic stability.
Several parameters are likely to contribute to this property. First,
gadopiclenol is characterized by high conformational rigidity, similar to
currently available macrocyclic GBCAs.40,41 Second, the addition of
substituted arms to the ligand structure introduces an additional steric
constraint, thus further enhancing the ligand's conformational rigidity.
Gd chelates can interact with both endogenous ligands (eg, phos-
phate) and endogenous metals (eg, Zn2+, Ca2+, and Fe2+/3+), as shown in
various in vitro and in vivo models.42–49 The clinical relevance of such
models has been discussed elsewhere.17,50–52 In vitro relaxivity mea-
surements have been conducted to assess the potential dechelation reac-
tion of gadopiclenol in the presence of phosphate and the endogenous
cation Zn2+. These experimentswere performed under sensitized condi-
tions to enable measurement of putative Gd dechelation, using a high-
concentration phosphate buffer with an equimolar mixture of GBCAse following intravenous bolus administration of 153Gd-gadopiclenol
© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
Investigative Radiology • Volume 54, Number 8, August 2019 Gadopiclenol Physicochemical Profile(gadopiclenol, gadoterate, and gadodiamide) and endogenous cations
(Zn2+). Under these conditions, the following reaction may occur:
Ligand GdþM2þ þ PO3−4 →Ligand M− þ GdPO4: Equation 5
where M is a divalent cation (Zn2+) that exchanges with Gd3+ in the
chelate, andPO3−4 is a phosphate anion that forms a precipitatewith Gd
3+.
In the presence of Zn2+ and PO3−4 , the R1(t)/R1(t0) ratio for gadodiamide
sharply decreased, suggesting dechelation followed by precipitation of
GdPO4. Conversely, the r1 relaxivities of gadopiclenol and gadoterate
remained constant over the experimental time in the presence of Zn2+
and PO3−4 , reflecting these complexes' stability toward dechelation in
the presence of phosphate and Zn2+.
Osmolality of the gadopiclenol solution is among the lowest
among GBCAs. The low volume administered during an MR exam-
ination should preclude physiological consequences of osmolality
(because of a low osmotic load12) and viscosity of the bolus.
A molecule's octanol-water (or PBS) partition coefficient is a
relevant and widely used measure of its hydrophilicity/lipophilicity
ratio.53 Log P value (measured in a 50/50 mixture of n-octanol and
pH 7.4 phosphate-buffered saline) is consistent with a high hydrophilic
structure. Direct comparison with log P values of other GBCAs (mea-
sured in butanol/water) is not possible.
The nonclinical pharmacokinetics investigations were per-
formed in dogs using 153Gd-labeled gadopiclenol. Since only the radio-
activity is detected in such experiments, radio-HPLCwas used to verify
that the 153Gd-gadopiclenol ratio exactly represented the bulk material,
as recommended.54 The distribution volume was consistent with
gadopiclenol distribution within the extracellular water compartment:
distribution volume at steady state (239 ± 8 mL/kg) was very similar
to the extracellular fluid volume measured by the ferrocyanide method
in dogs (237± 27 mL/kg).55 Twenty-four hours after administration of
gadopiclenol, almost all the injected dosewas found to be excretedmostly
in urine. No metabolites were found, no plasma protein binding was ev-
idenced, and no sex-related effects were identified. Overall, the results
demonstrated that gadopiclenol pharmacokinetics parameters were very
similar to those of other extracellular and nonspecific GBCAs.56
Fries et al57 performed a study in rats, comparing the signal-
to-noise ratios of hepatic colorectal metastases and of healthy he-
patic parenchyma, lesion enhancement, and contrast-to-noise ratio
for gadopiclenol and gadobutrol (both intravenously injected at
0.1 mmol Gd/kg) at 9.4 T. They reported significantly better lesions
enhancement with gadopiclenol compared with gadobutrol. In-
deed, the current advent of MRI systems operating at high and
ultra-high magnetic fields opens new avenues in neuroradiol-
ogy.4,58 Importantly, the high relaxivity of gadopiclenol in high
fields overcomes the issues associated with the low relaxivity of
currently available GBCAs in high fields.
Gd-enhanced MRI is crucial for the detection of small metas-
tases2,4,59 and further allows the distinction of metastases from
nontumor white matter lesions.2 Several clinical studies show bene-
fits associated with using higher doses of GBCAs. Administration of
an additional 0.2 mmol Gd/kg at 30 minutes after the clinical dose of
0.1 mmol Gd/kg of a nonspecific GBCA reportedly improves CNS
metastasis detection and lesion conspicuity, sometimes leading to
modification of the therapeutic strategy.5,60,61 In addition, single ad-
ministration of 0.3 mmol Gd/kg has been successfully used for the
detection of CNS metastases.62 The high relaxivity and stability
properties of gadopiclenol support its potential use at lower doses
than classic extracellular GBCAs, allowing equivalent visualization
with a higher benefit/risk balance, and its potential to be adminis-
tered at the current Gd dose of 0.1 mmol/kg, while providing better
visualization of CNS lesions due to its very high relaxivity. This
may dramatically impact patient management, for example, with
regards to selection of surgical resection, stereotactic radiosurgery,© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.whole-brain radiation surgery, and so on.4 Further, this GBCAwith
almost constant relaxivity and no protein binding may facilitate
quantitative MRI.4
In conclusion, our present report summarized the physicochem-
ical and pharmacokinetic profiles of gadopiclenol, a new extracellular
and macrocyclic nonspecific Gd chelate that exhibits high relaxivity,
no protein binding, high kinetic inertness, and a pharmacokinetic
profile similar to that of other extracellular nonspecific GBCAs.
Gadopiclenol is currently undergoing clinical development.63
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